Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors

Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors

Checkpoint inhibitors (CPIs) increase antitumor activity by unblocking regulators of the immune response. This action can provoke a wide range of immunologic and inflammatory side effects, some of which can be fatal. Recent studies suggest that CPI-induced immune-related adverse events (irAEs) may p...

Full description

Bibliographic Details
Main Authors: Lynn M. Rose, Hannah A. DeBerg, Prakash Vishnu, Jason K. Frankel, Adarsh B. Manjunath, John Paul E. Flores, David M. Aboulafia
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Oncology
Subjects:
checkpoint inhibitors
immunotherapy
immune-related adverse events
biomarkers
survival benefits
preexisting conditions
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.570752/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.570752/full

Similar Items